Neuropeptide Therapy of Recent Onset Type 1 Diabetes

Inclusion Criteria: * Recent onset T1D (CDA 2013 guidelines: See link in links section * Age 10-18 years * Disease Duration 3-30 months * Fasting C-Peptide (measured at screening) greater than or equal to 33 pmol/L * Post honeymoon phase based on the following criteria: History of HbA1c values and insulin requirements from diagnosis indicating a honeymoon period followed by increased insulin requirements which at time of recruitment are \> 0.50 units/Kg together with an HbA1c value \> 7.2 %; Patients with diabetes duration \> 3 months who never experienced a honeymoon period as reflected by consistent HbA1c values \> 7.2 % from the time of diagnosis and at the time of recruitment are using an insulin dose \> 0.50 units/Kg. * The presence of one or more of the TRPV1 alleles similar to those found in patients currently enrolled in the TRPV1-North American - European Study. * Stimulated C-Peptide (measured at mixed meal tolerance at Stage A and Stage B of sP trial) ≥ 200 pmol/L and less than or equal to 1500 pmol/L. Exclusion Criteria: * Patients with known co-morbidities, including ACE-inhibitor treated hypertension as well as chromosomal abnormalities, involving one or more organ systems. * Type 2 Diabetes Mellitus * Patients with a known radiographic contrast allergy * Pregnancy.